James Taylor1, Sarah Dunkerley2, David Silver3, Andrew Redfern4, Nick Talbot5, Ian Sharpe6, Paul Guyver7. 1. Department of Radiology, Royal Devon and Exeter Hospital, Exeter, UK. Electronic address: james.taylor22@nhs.net. 2. Department of Orthopaedic Surgery, Royal Devon and Exeter Hospital, Exeter, UK. Electronic address: sdunkerley@doctors.org.uk. 3. Department of Radiology, Royal Devon and Exeter Hospital, Exeter, UK. Electronic address: davidsilver@nhs.net. 4. Department of Radiology, Royal Devon and Exeter Hospital, Exeter, UK. Electronic address: andrewredfern@nhs.net. 5. Department of Orthopaedic Surgery, Royal Devon and Exeter Hospital, Exeter, UK. Electronic address: nick.talbot@nhs.net. 6. Department of Orthopaedic Surgery, Royal Devon and Exeter Hospital, Exeter, UK. Electronic address: iansharpe@nhs.net. 7. Department of Orthopaedic Surgery, Royal Devon and Exeter Hospital, Exeter, UK. Electronic address: paul.guyver@nhs.net.
Abstract
BACKGROUND: Achilles tendinopathy (AT) represents a triad of tendon pain, swelling and impaired performance. Extracorporeal shockwave therapy (ESWT) has been endorsed by the National Institute for Health and Care Excellence (NICE) for refractory AT. This audit investigates the long-term outcomes of patients treated with ESWT for refractory AT. METHODS: Forty-six patients treated with ESWT for AT between October 2010 and August 2011 completed visual analogue, satisfaction scores and functional assessment questionnaires over two years. Patients were subdivided into two groups depending on whether their AT was insertional (IAT) or non-insertional (NAT). RESULTS: Forty-six patients (mean age 58 years) completed all treatments and full 2 year follow up. There was significant improvement in pain at rest, on activity and of function within both NAT and IAT groups over the two-year period. Satisfaction scores were significant in the NAT group but not in the IAT group. CONCLUSIONS: ESWT appears to be of benefit in the long term improvement of pain at rest, on activity and functional outcome in patients with refractory AT. However, subjective patient opinion may not match the perceived clinical outcome observed in this audit in all patients and individuals should be counselled regarding this prior to treatment.
BACKGROUND:Achilles tendinopathy (AT) represents a triad of tendon pain, swelling and impaired performance. Extracorporeal shockwave therapy (ESWT) has been endorsed by the National Institute for Health and Care Excellence (NICE) for refractory AT. This audit investigates the long-term outcomes of patients treated with ESWT for refractory AT. METHODS: Forty-six patients treated with ESWT for AT between October 2010 and August 2011 completed visual analogue, satisfaction scores and functional assessment questionnaires over two years. Patients were subdivided into two groups depending on whether their AT was insertional (IAT) or non-insertional (NAT). RESULTS: Forty-six patients (mean age 58 years) completed all treatments and full 2 year follow up. There was significant improvement in pain at rest, on activity and of function within both NAT and IAT groups over the two-year period. Satisfaction scores were significant in the NAT group but not in the IAT group. CONCLUSIONS: ESWT appears to be of benefit in the long term improvement of pain at rest, on activity and functional outcome in patients with refractory AT. However, subjective patient opinion may not match the perceived clinical outcome observed in this audit in all patients and individuals should be counselled regarding this prior to treatment.
Authors: Karin Grävare Silbernagel; Peter Malliaras; Robert-Jan de Vos; Shawn Hanlon; Mitchel Molenaar; Håkan Alfredson; Inge van den Akker-Scheek; Jarrod Antflick; Mathijs van Ark; Kenneth Färnqvist; Zubair Haleem; Jean-Francois Kaux; Paul Kirwan; Bhavesh Kumar; Trevor Lewis; Adrian Mallows; Lorenzo Masci; Dylan Morrissey; Myles Murphy; Richard Newsham-West; Richard Norris; Seth O'Neill; Koen Peers; Igor Sancho; Kayla Seymore; Patrick Vallance; Arco van der Vlist; Bill Vicenzino Journal: Sports Med Date: 2021-11-19 Impact factor: 11.136
Authors: Vito Pavone; Luca Cannavò; Antonio Di Stefano; Gianluca Testa; Luciano Costarella; Giuseppe Sessa Journal: Biomed Res Int Date: 2016-10-24 Impact factor: 3.411